|
Malignant neoplasm of breast
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs.
|
31182803 |
2019 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
NET dose-dependently increased BC cell viability and this effect was accompanied by increased expression of PGRMC1.
|
29907248 |
2018 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
A recent study showed that increased plasma levels of the NET biomarker, citrullinated histone H3 (H3Cit), are associated with venous thromboembolism in pancreatic and lung cancer but not in other types of cancer, including breast cancer.
|
31048354 |
2020 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity.
|
31018569 |
2019 |
|
Breast Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs.
|
31182803 |
2019 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity.
|
31018569 |
2019 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
A recent study showed that increased plasma levels of the NET biomarker, citrullinated histone H3 (H3Cit), are associated with venous thromboembolism in pancreatic and lung cancer but not in other types of cancer, including breast cancer.
|
31048354 |
2020 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
NET dose-dependently increased BC cell viability and this effect was accompanied by increased expression of PGRMC1.
|
29907248 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cases in which the primary cannot be located are referred to as NET with CUP-syndrome (cancer of unknown primary syndrome).
|
21681495 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Family history of any cancer, family history of colorectal cancer and history of ever smoking were associated with an increased risk of SI-NET by meta-analysis.
|
28394712 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A recent study showed that increased plasma levels of the NET biomarker, citrullinated histone H3 (H3Cit), are associated with venous thromboembolism in pancreatic and lung cancer but not in other types of cancer, including breast cancer.
|
31048354 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NET-U represents an aggressive form of uterine malignancy.
|
31074241 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Bioinformatic analysis of cancer RNA-seq data shows that hsa-miR-155-5p and ELK3 expression are significantly anti-correlated, as would be expected from hsa-miR-155-5p targeting ELK3 RNA.
|
25401928 |
2014 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no relationship between C. albicans MLST profiles and their geographic distribution, cancer type and SAP2 gene expression.
|
31630914 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nevertheless, K-ras mutation screening may increase the sensitivity of FNA and ERP cytology and may be useful in identifying pancreatitis patients at high risk for developing cancer, and as a adjunct with cytology to differentiate pancreatic cancer from chronic pancreatitis.
|
14966900 |
2004 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, we identified the molecular mechanism by which ELK3 promotes cancer cell migration and invasion.
|
27959451 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We present a case of a 58-year-old adult patient with dyspeptic symptoms who was incidentally diagnosed with triple malignancy (pheochromocytoma, multiple GISTs of small intestine and an ampullary NET) as a first manifestation of NF1.
|
31301733 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In MDA-MB-231 breast cancer cells, knockdown of RSK2 or ELK3 suppressed cell proliferation with accumulation at the G1 cell cycle phase, resulting in inhibition of foci formation and anchorage-independent cancer colony growth in soft agar.
|
31018569 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with metastatic high-grade (WHO G3) gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC) represent a heterogeneous subgroup with poor prognosis and standard platinum-etoposide chemotherapy has limited therapeutic benefit.
|
31846429 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SCML2 expression in GEP-NETs was associated with several clinicopathological parameters, such as histological type, tumor grade, depth of invasion and clinical stage.
|
28810646 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study used a virtual touch tissue imaging and quantification (VTIQ) method to investigate the change in elasticity in xenograft tumor tissue models following silencing of the neuroepithelial-transforming protein 1 (<i>NET-1</i>) gene by ultrasound-targeted microbubble destruction (UTMD).
|
30127877 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PD1 expression varied across tumor type with SCCO (100 %), SCCO-HT (60 %), NET-O (33 %) vs SCLC (42 %).
|
27566252 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One of the main obstacles to improve current treatments is represented by the impermeability of the blood vessels residing within nervous tissue as well as of the new vascular net generating from the tumor, commonly referred to as blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB), respectively.
|
31137689 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These biomarkers include (1) peptides and growth factors; (2) DNA and RNA markers based on genomics analysis, for example, the so-called NET test, which has been developed for analyzing gene transcripts in circulating blood; (3) circulating tumor/endothelial/progenitor cells or cell-free tumor DNA, which represent minimally invasive methods that would provide additional information for monitoring treatment response and (4) improved imaging techniques with novel radiolabeled somatostatin analogs or peptides.
|
30615596 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FSHR expression was evaluated in tumor samples from 30 patients with p-NET by immunohistochemistry and Western blot; fluorescence microscopy was used to localize FSHR in specific cells from tissue samples. von Willebrand factor (vWF) and chromograninA (chrA) was used as blood vessel and NET cells marker, respectively, to co-localize FSHR.
|
22732316 |
2013 |